Q3 2022 EPS Estimates for Bavarian Nordic A/S (OTCMKTS:BVNRY) Boosted by Jefferies Financial Group

Bavarian Nordic A/S (OTCMKTS:BVNRYGet Rating) – Jefferies Financial Group lifted their Q3 2022 EPS estimates for shares of Bavarian Nordic A/S in a report released on Monday, September 19th. Jefferies Financial Group analyst P. Welford now forecasts that the company will earn $0.13 per share for the quarter, up from their previous forecast of ($0.23). The consensus estimate for Bavarian Nordic A/S’s current full-year earnings is ($0.31) per share. Jefferies Financial Group also issued estimates for Bavarian Nordic A/S’s Q4 2022 earnings at ($0.02) EPS, FY2022 earnings at ($0.14) EPS, FY2023 earnings at $1.01 EPS and FY2024 earnings at $0.76 EPS.

Separately, Cowen raised Bavarian Nordic A/S from a “market perform” rating to an “outperform” rating in a research report on Wednesday, July 20th.

Bavarian Nordic A/S Stock Down 7.8 %

Shares of OTCMKTS:BVNRY opened at $9.87 on Wednesday. The firm has a fifty day simple moving average of $14.01 and a two-hundred day simple moving average of $10.66. Bavarian Nordic A/S has a 52 week low of $5.85 and a 52 week high of $19.31. The stock has a market capitalization of $2.09 billion, a P/E ratio of -20.56 and a beta of 1.49.

Bavarian Nordic A/S Company Profile

(Get Rating)

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

See Also

Earnings History and Estimates for Bavarian Nordic A/S (OTCMKTS:BVNRY)

Receive News & Ratings for Bavarian Nordic A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic A/S and related companies with MarketBeat.com's FREE daily email newsletter.